Results 91 to 100 of about 648,498 (303)

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Adjuvant chemotherapy for rectal cancer with complete pathological response (pCR) may not be necessary: a pooled analysis of 5491 patients

Cancer Cell International, 2019
Background It is recommended postoperative adjuvant chemotherapy for all rectal cancers undergoing neo-chemoradiotherapy regardless of the final yield pathology.
Xiang Hu, Ya-Qi Li, Xiao-ji Ma, Long Zhang, San-Jun Cai, Jun-Jie Peng   +5 more
doaj   +1 more source

Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis

Molecular Oncology, EarlyView.
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht, Sameer Gupta, Amrita Chaurasia, Manisha Sachan   +3 more
wiley   +1 more source

Hereditary colorectal cancer : assessment of genotype-phenotype correlations and analysis of rare susceptibility genes in familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) [PDF]

, 2008
Each year 3500 people in Switzerland are diagnosed with colorectal cancer. Approximately 20 percent of all affected patients have two or more first or second-degree relatives with colorectal cancer (at-risk family members). About five percent of these
Necker, Judith
core   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Study protocol for BeWEL: The impact of a BodyWEight and physicaL activity intervention on adults at risk of developing colorectal adenomas [PDF]

, 2011
Background: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second highest cause of cancer death in the UK. Most cases occur in people over 50 years and CRC often co-exists with other lifestyle related disorders including ...
Belch, Jill J F, Steele, RJC, Anderson, Annie, Steele, Robert J C, Jackie Rodger, Angela M Craigie, Treweek, S, Daly, Fergus, Stead, Martine, Annie S Anderson, Steele, R J, Anderson, A S, Kirk, A, Caswell, Stephen, Ludbrook, Anne, Wardle, J., Anne Ludbrook, Caswell, S, Belch, JJF, Ludbrook, A, Jill JF Belch, Craigie, Angela M, Steele, Robert J. C., Fergus Daly, Alison Kirk, Treweek, S., Joyce Thompson, Anderson, Annie S.; id_orcid, Craigie, Angela M.; id_orcid, Belch, Jill J. F.; id_orcid, Shaun Treweek, Craigie, AM, Belch, Jill, Craigie, A, Kirk, Alison, Jane Wardle, Wardle, Jane, Martine Stead, Stephen Caswell, Belch, J, Paterson, C, Anderson, AS, Anderson, Annie S, Treweek, Shaun, Stead, M, Paterson, Caron, Rodger, Jackie, Caron Paterson, Rodger, J, Thompson, J, Robert JC Steele, Steele, Robert, Thompson, Joyce, Craigie, Angela, Wardle, J, Daly, F   +55 more
core   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Risk and Management of Bowel Obstruction in Colorectal Cancer Patients Undergoing Immunotherapy: A Cross-Sectional Multicenter Study

ImmunoTargets and Therapy
Zhi-Gang Hong,1,2,* Binyi Xiao,1,2,* Muxu Zheng,1,2,* Wanjun Yang,1,2,* Liangjun Zhu,3 Guodong Liang,4 Yuhao Luo,5 Jinghua Tang,1,2 Weijian Mei,1,2 Jie-Hai Yu,1,2 Zhenlin Hou,1,2 Xiaojun Wu,1,2 Peirong Ding,1,2 Wu Jiang1,2
Hong ZG, Xiao B, Zheng M, Yang W, Zhu L, Liang G, Luo Y, Tang J, Mei W, Yu JH, Hou Z, Wu X, Ding P, Jiang W   +13 more
doaj  

Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study

npj Precision Oncology
Standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC) is associated with significant toxicity and limited pathological responses.
Yanlong Liu, Shihui Zhao, Fenqi Du, Songtao Du, Liqiang Song, Tianyi Xia, Bomiao Zhang, Binbin Cui   +7 more
doaj   +1 more source